New study shows promise of ALung’s Hemolung technology to help protect the injured lung

Study results published in the journal Critical Care show that the Hemolung RAS can safely facilitate an ultra-protective ventilation strategy. PITTSBURGH  (February 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the publication of new results from an (read more)

The use of extracorporeal carbon dioxide removal to avoid intubation in patients failing non-invasive ventilation – a cost analysis

25 November 2015 Clinical Update, Recent News

  Background To evaluate the economic implications of the pre-emptive use of extracorporeal carbon dioxide removal (ECCO2R) to avoid invasive mechanical ventilation (IMV) in patients with hypercapnic ventilatory insufficiency failing non-invasive ventilation (NIV). Methods Retrospective ancillary cost analysis of data extracted from a recently published multicentre case–control-study (n = 42) on the use of arterio-venous ECCO2R to (read more)

Early experience of low flow extracorporeal carbon dioxide removal in management of acute hypercapnic respiratory failure

Dr. Ravi Tiruvoipati presented the initial Australian experience with low-flow extracorporeal carbon dioxide removal (Hemolung RAS) at the 2015 Australian and New Zealand Intensive Care Society (ANZICS) meeting. Early experience of low flow extracorporeal carbon dioxide removal in management of acute hypercapnic respiratory failure from alungtech (read more)

Ultra-low tidal volumes and extracorporeal carbon dioxide removal (Hemolung RAS) in ARDS patients. A clinical feasibility study.

Ultra-low tidal volumes and extracorporeal carbon dioxide removal (Hemolung RAS) in ARDS patients. A clinical feasibility study FJ Parrilla*, L Bergesio, H Aguirre-Bermeo, JC Suarez, P López, I Morán, J Mancebo From ESICM LIVES 2015 Berlin, Germany. 3-7 October 2015 Summary: Objective: To evaluate the effect of extracorporeal CO2 removal in ARDS during ultraprotective ventilation in terms of (read more)

Case series of protective ventilation for ARDS using partial extracorporeal CO2 removal

Rauch S.1, Roth H.2, Deininger T.2, Kuhwald A.2, Lund L.3, Fischer M.1 1ALB FILS KLINIKEN, Anesthesiology, Göppingen, Germany, 2ALB FILS KLINIKEN, Internal Medicine, Göppingen, Germany, 3ALung Technologies Inc., Pittsburgh, United States Poster presentation from the EuroELSO 2015 4th International Congress Objectives In the ARDS Network trial of low tidal volume ventilation, hypercapnia and respiratory acidosis (read more)

University of Maryland Second in USA to use Hemolung RAS

Hemolung RAS used under emergency use rules to facilitate extubation and lung recovery in a patient with COPD due to alpha-1 antitrypsin deficiency. (read more)

“Respiratory Dialysis for Acute Respiratory Failure” – Workshop Summary

15 November 2013 Clinical Update

Positive clinical experience with the Hemolung RAS presented at ESICM 2013 (read more)

New Publication: “Respiratory Dialysis for Avoidance of Intubation in Acute Exacerbation of COPD”

14 November 2013 Clinical Update, Recent News

A new article titled Respiratory Dialysis for Avoidance of Intubation in Acute Exacerbation of COPD was published in the November/December 2013 edition of the ASAIO Journal. The authors describe two successful cases using the Hemolung RAS to provide minimally invasive extracorporeal carbon dioxide removal (ECCO2R), or Respiratory Dialysis, for the purpose of avoiding intubation in acute (read more)